Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2568-2575

  Morgan, Amy S ^a   Sanderson, Polly E ^a   Borch, Richard F ^b   Tew, Kenneth D ^c   Niitsu, Yoshiro ^d   Takayama, Tetsuji ^d   Von Hoff, Daniel D ^e   Izbicka, Elzbieta ^e   Mangold, Gina ^e   Paul, Christer ^f   Broberg, Ulrika ^f   Mannervik, Bengt ^g   David Henner, W ^h   Kauvar, Lawrence M ^a,i  

^a Terrapin Technologies Inc   (United States)

^b PURDUE UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e CTRC Institute for Drug Development   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANFOSFAMIDE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTOTOXIN; DOXORUBICIN; GAMMA GLUTAMYL ALPHA AMINO BETA [[2 ETHYL N,N,N',N' TETRAKIS(2 CHLOROETHYL)PHOSPHORODIAMIDATE]SULFONYL]PROPIONYL PHENYLGLYCINE; GLUTATHIONE TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER INHIBITION; CARCINOMA; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYTOTOXINS; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; PRODRUGS; SUBRENAL CAPSULE ASSAY; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 17544385571     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. DeVita, V. T., Jr. Principles of Chemotherapy. In: DeVita, V. T., Jr. Hellman, S., and Rosenberg, S. A. (eds.), Cancer: Principles and Practice of Oncology, Ed. 4, pp. 276-292. Philadelphia: J. B. Lippincott Co., 1993.
2. Grunherg, S. M., Lane, M., Lester, E. P., Sridhar, K. S., Mortimer, J., Murphy, W., and Sanderson, P. E. A randomized double-blind comparison of three dose levels of intravenously administered ondansetron in the prevention of nausea and vomiting associated with high dose cisplatin chemotherapy. J. Natl. Cancer Inst., 32: 268-272, 1993.
3. Cohen, A. M., Zsebo, K. M., Inoue, H., Hines, D., Boone, T. C., Chazin, V. R., Tsai, L., Ritch, T., and Souza, L. M. In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc. Natl. Acad. Sci. USA, 84: 2484-2488, 1987.
4. Poplin, E., Smith, H., Behrens, B., Redman, B., Flaherty, L., Neidhart, J., and Alberts, D. SWOG 8825: melphalan GM-CSF: a Phase I study. Gynecol. Oncol., 44: 66-70, 1992.
5. Capizzi, R. L., Scheffer, B. J., and Schein, P. S. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer (Phila.), 72: 3495-3501, 1993.
6. Melton, R. G., and Sherwood, R. F. Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst., 88: 153-165, 1996.
7. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
8. Husain, I., Mohler, J. L., Leigler, H. F., and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54: 539-546, 1994.
9. Mannervik B., Awasthi, Y. C., Board, P. G., Hayes, J. D., Di Ilio, C., Ketterer, B., Listowsky, I., Morgenstern, R., Muramatsu, M., Pearson, W. R., Pickett, C. B., Sato, K., Widersten, M., and Wolf, R. Nomenclature for human glutathione transferases. Biochem. J., 282: 305-306, 1992.
10. Shea, T. C., Kelley, S. L., and Henner, W. D. Identification of an anionic form of glutathione transferase present in many human tumors and human tumor cell lines. Cancer Res., 48: 527-533, 1988.
11. Castro, V. M., Soderstrom, M., Carlberg, I., Widersten, M., Platz, A., and Mannervik, B. Differences among human tumor cell lines in the expression of glutathione transferases and other glutathione-linked enzymes. Carcinogenesis (Lond.), 11: 1569-1576, 1990.
12. Mannervik, B., Castro, V. M., Danielson, U. H., Tahir, M. K., Hansson, J., and Ringborg, U. Expression of class Pi glutathione transferase in human malignant melanoma cells. Carcinogenesis (Lond.), 8: 1929-1932, 1987.
13. Montali, J. A., Wheatley, J. B., and Schmidt, D. E., Jr. Comparison of GST levels in predicting the efficacy of a novel alkylating agent. Cell. Pharmacol., 2: 241-247, 1996.
14. Moscow, J. A., Fairchild, C. R., Madden, M. J., Ransom, D. T., Wieland, H. S., O'Brien, E. E., Poplack, D. G., Cossman, J., Myers, C. E., and Cowan, K. H. Expression of anionic glutathione S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res., 49: 1422-1428, 1989.
15. Nishimura, T., Newkirk, K., Sessions, R. B., Andrews, P. A., Trock, B. J., Rasmussen, A. A., Montgomery, E. A., Bischoff, E. K., and Cullen, K. J. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin. Cancer Res., 2: 1859-1865, 1996.
16. Tew, K. D., Monks, A., Barone, L., Rosser, D., Akerman, G., Montali, J. A. Wheatley, J. B., and Schmidt, D. E., Jr. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute drug screening program. Mol. Pharmacol., 50: 149-159, 1996.
17. Saint-Ruf, C., Malfoy, B., Scholl, S., Zafrani, B., and Dutrillaux, B. GSTπ gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers. Oncogene, 6: 403-406, 1991.
18. Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res., 54: 4313-4320, 1994.
19. Ciaccio, P. J., Tew, K. D., and La Creta, F. P. Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. Biochem. Pharmacol., 42: 1504-1507, 1991.
20. Yuan, Z-M., Smith, P. B., Brundrett, R. B., Colvin, M., and Fenselau, C. Glutathione conjugation with phosphoramide mustard and cyclophosphamide: a mechanistic study using tandem mass spectrometry. Drug Metab. Dispos., 19: 625-629, 1991.
21. Moscow, J. A., Townsend, A. J., and Cowan, K. H. Elevation of π class glutathione S-transferase activity in human breast cancer cells by transfection of the GSTπ gene and its effect on sensitivity to toxins. Mol. Pharmacol., 36: 22-28, 1989.
22. Harris, W. R., Morrow, C. S., and Townsend, A. J. Transgenic human glutathione S-transferase pi protects against DNA damage by benzo(a)pyrene diol-epoxide in human T47D cells. Proc. Am. Assoc. Cancer Res., 34: 756, 1993.
23. Greenbaum, M., Letourneau, S., Assar, H., Schecter, R. L., Batist, G., and Coumoyer, D. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH3T3 mouse fibroblasts. Cancer Res., 54: 4442-4447, 1996.
24. Ban, Y., Takhashi, T., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., and Niitsu, Y. Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res., 56: 3577-3582, 1996.
25. Morgan, A. S., Ciaccio, P. J., Tew, K. D., and Kauvar, L. M. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother. Pharmacol., 37: 363-370, 1996.
26. Hamada, S., Kamada, M., Furumoto, H., Hirao, T., and Aono, T. Expression of glutathione S-transferase-π in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol. Oncol., 52: 313-319, 1994.
27. Green, J. A., Robertson, L. J., and Clark, A. H. Glutathione S-transferase expression in benign and malignant ovarian tumours. Br. J. Cancer, 68: 235-239, 1993.
28. Tidefelt, U., Elmhorn-Rosenborg, A., Paul, C., Hao, X. Y., Mannervik, B., and Eriksson, L. C. Expression of glutathione transferase π as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res., 52: 3281-3285, 1992.
29. Gilbert, L., Elwood, L. J., Merino, M., Massod, S., Barnes, R., Steinberg, S. M., Lazarous, D. F., Pierce, L., d'Angelo, T., Moscow, J. A., Townsend, A. J., and Cowan, K. H. A pilot study of π-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J. Clin. Oncol., 11: 49-58, 1991.
30. Frierson, H. F., Jr., Gaffey, M. J., Meredith, S. D., Boyd, J. C., and Williams, M. E. Immunonistochemical staining and Southern blot hybridization for glutathione S-transferase π in mammary infiltrating ductal carcinoma. Mod. Pathol., 8: 643-647, 1995.
31. Ciaccio, P. J., Shen, H., Jaiswal, A. K., Lyttle, M. H., and Tew, K. D. Modulation of detoxification gene expression in human colon HT29 cells by glutathione S-transferase inhibitors. Mol. Pharmacol., 48: 639-647, 1995.
32. Lyttle, M. H., Satyam, A., Hocker, M. D., Bauer, K. E., Caldwell, C. G., Hui, H. C., Morgan, A. S., Mergia, A., and Kauvar, L. M. Glutathione S-transferase activates novel alkylating agents. J. Med. Chem., 37: 1501-1507, 1994.
33. Satyam, A., Hocker, M. D., Kane-Maguire, K. A., Morgan, A. S., Villar, H. O., and Lyttle, M. H. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J. Med. Chem., 39: 1736-1747, 1996.
34. Wang, R. W., Newton, D. J., Huskey, S. E. W., McKeever, B. M., Pickett, C. B., and Lu, A. Y. H. Site directed mutagenesis of glutathione S-transferase YaYa. J. Biol. Chem., 267: 19866-19871, 1992.
35. Widersten, M., Kolm R. H., Bjornestedt, R., and Mannervik, B. Contribution of five amino acid residues in the glutathione-binding site to the function of human glutathione transferase P1-1. Biochem. J., 285: 377-381, 1992.
36. Stenberg, G., Board, P. G., and Mannervik, B. Mutation of an evolutionarily conserved tyrosine residue in the active site of a human class α glutathione transferase. FEBS Lett., 293: 153-155, 1991.
37. Frei, E. III, Teicher, B. A., Holden, S. A., Cathecart, K. N. S., and Wang, Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res., 48: 6417-6423, 1988.
38. Sreeama, L., and Sladek, N. E. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res., 54: 2176-2185, 1994.
39. Nakagawa, K., Saijo, N., Tsuchida, S., Sakai, M., Tsunokawa, Y., Yokota, J., Muramatsu, M., Sato, K., Terada, M., and Tew, K. D. Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines. J. Biol. Chem., 266: 4296-4301, 1990.
40. Kelley, M. K., Montali, J. A., Engqvist-Goldstein, A. E., Wheatley, J. B., Schmidt, D. E., Jr., and Kauvar, L. M. Variability of hexyl-glutathione binding proteins in matched normal and cancer breast tissue. Biochem. J., 304: 843-848, 1994.
41. Oliver, M. H., Harrison, N. K., Bishop, J. E., Cole, P. J., and Laurent, G. J. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J. Cell Sci., 92: 513-518, 1989.
42. Salmon, S. E., Hamburger, A. W., Soehnlen, B., Durie, B. G., Alberts, D. S., and Moon, T. E. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N. Engl. J. Med., 298: 1321-1327, 1978.
43. Böyum, A. Isolation of leucocytes from human blood. Scand. J. Clin. Lab. Invest. Suppl., 97: 31-50, 1968.
44. Sundman-Engberg, B., Tidefelt, U., Liliemark, J., and Paul, C. Intracellular concentrations of anticancer drugs in leukemic cells in vitro versus in vivo. Cancer Chemother. Pharmacol., 25: 252-256, 1990.
45. Rhedin, A. S., Tidefelt, U., Jonsson, K., Lundin, A., and Paul, C. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk. Res., 17: 271-276, 1993.
46. Niwa, K., Yamada, K., Furukawa, T., Shudo, N., Seto, K., Matsumoto, T., Takao, S., Akiyama, S., and Shimazu, H. Effect of a dihydropyridine analogue, 2-[benzyl-(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1- (2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumor cells to Adriamycin. Cancer Res., 52: 3655-3660, 1992.
47. Flatgaard, J. E., Bauer, K. E., and Kauvar, L. M. Isozyme specificity of novel glutathione S-transferase inhibitors. Cancer Chemother. Pharmacol., 33: 63-70, 1993.
48. Paul, K. D., Hamel, E., and Malspeis, L. Prediction of biochemical mechanism of action from in vitro antitumor screen of National Cancer Institute cell panel. In: W. O. Foye (ed.), Cancer Chemotherapeutic Agents. Washington DC: ACS Books, 1995.
49. Von Hoff, D. D. He's not going to talk about in vitro predictive assays again, is he? J. Natl. Cancer Inst., 82: 96-101, 1990.
50. Izbicka, E., Lawrence, R., Cerna, C., Von Hoff, D. D., and Sanderson, P. E. Activity of TER286 against human tumor colony forming units. Anticancer Drugs, 8: 1-4, 1997.
51. Dimanche-Boitrel, M-T., Pelletier, H., Genne, P., Petit, J-M., Le Grimellec, C., Cana, P., Ardiet, C., Bastian, G., and Chauffert, B. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int. J. Cancer, 50: 677-682, 1992.
52. Bodensteiner, D. C., and Doolittle, G. C. Adverse haematological complications of anticancer drugs: clinical presentation, management and avoidance Drug Safety, 8: 213-224, 1993.
53. Millar, J. L., Hudspith, B. N., McElwain T. J., and Phelps, T. A. Effect of high dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br. J. Cancer, 38: 137-142, 1978.
54. Yeager, A. M. Levin, F. C., and Levin, J. Effect of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels. J. Cell. Physiol., 112: 222-228, 1982.
55. Smith, M. T., Evans, C. G., Doane-Setzer, P., Castro, V., Tahir, M. K., and Mannervik, B. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosurea by class μ glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res., 49: 2621-2625, 1989.
56. O'Dwyer, P. J., La Creta, F., Nash, S., Tinsley, P. W., Schilder, R., Clapper, M. L., Tew, K. D., Panting, L., Litwin, S., and Comis, R. L. Phase I study of thiotepa in combination with the glutathione S-transferase inhibitor ethacrynic acid. Cancer Res., 51: 6059-6065, 1991.
57. Lee, W-H., Morton, R. A., Epstein, J. A., Brooks, J. D., Campbell, P. A., Gova, G. S., Hsieh, W-S., Isaacs, W. B., and Nelson, W. G. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA, 91: 11733-11737, 1994.
58. Kauvar, L. M., Lyttle, M. H., and Satyam, A. GST-activated compounds. U. S. Patent Nos. 5,545,621 and 5,556,942, 1996.